The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics.Called Amtagvi, or lifileucel, the drug is the first individualized tumor-infiltrating lymphocyte (TIL) therapy to reach the market. The FDA on Friday […]
